NCT02386098

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

A Phase 2b Randomized, Active-Controlled, Staged, Open-Label Trial to Investigate Safety and Efficacy of BMS-955176/GSK3532795 in Combination With Dolutegravir and Atazanavir (With or Without Ritonavir) in Treatment-Experienced HIV-1 Infected Adults

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) \[with or without ritonavir (RTV)\] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	BMS-955176	HIV Maturation Inhibitor
DRUG	Atazanavir (ATV)	Atazanavir
DRUG	Ritonavir (RTV)	Ritonavir
DRUG	Dolutegravir (DTG)	Dolutegravir
DRUG	Tenofovir (TDF)	Tenofovir

Timeline

• Start date: 2015-07-08
• Primary completion: 2017-06-07
• Completion: 2017-06-07
• First posted: 2015-03-11
• Last updated: 2018-08-20
• Results posted: 2018-08-20

Locations

64 sites across 13 countries: United States, Argentina, Australia, Canada, Chile, Colombia, Mexico, Peru, Puerto Rico, Russia, South Africa, Taiwan, Thailand

Regulatory

• FDA-regulated drug study